<![CDATA[France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma]]>
Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) by France’s National Agency for Medicines and Health …